

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated average burden nours per response 0.5				
nours per response				

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)									
Name and Address of Reporting Person * Reich Michael	Statem	2. Date of Event Requiring Statement (Month/Day/Year) 03/27/2007		3. Issuer Name and Ticker or Trading Symbol Opko Health, Inc. [OPK]					
(Last) (First) (Middle OPKO HEALTH, INC., 4400 BISCAYNE BOULEVARD	03/2/			4. Relationship o Issuer (Check	all applicable)		5. If Amendment, Date Original Filed(Month/Day/Year) 03/29/2007		
(Street) MIAMI, FL 33137				X Director 10% Owner Officer (give title below) Other (specify below)			6. Individual or Joint/Group FilingCheck Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)		Table I - Non-Derivative Securities Beneficially Owned					, , ,		
1.Title of Security (Instr. 4)		Ber	Amount of Secretically Ownerstr. 4)	Securities 3. Ownership		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock, \$0.01 par value		359	59,566		D				
Common Stock, \$0.01 par value		194	4,604		I	See fo	ootnote (1)		
Reminder: Report on a separate line for each of Persons who requires the form Table II - Deri	spond to the displays a c	collection o urrently valid	f information d OMB contr	n contained in		·			
1. Title of Derivative Security (Instr. 4)	2. Date Exe Expiration I (Month/Day/Ye		3. Title and Amount of Securities Underlying Derivati Security (Instr. 4)		Price of Derivative	For Der Sec	Ownership m of rivative curity:	6. Nature of Indirect Beneficia Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shar	Security	Ind	Direct (D) or Indirect (I) (Instr. 5)		
Warrant (Right to Buy)	(2)	03/27/2017	Common Stock	10,901	\$ 0.6728		D		
Warrant (Right to Buy)	<u>(2)</u>	03/27/2017	Common Stock	10,901	\$ 0.8473		D		
Warrant (Right to Buy)	<u>(2)</u>	03/27/2017	Common Stock	10,901	\$ 1.0466		D		
Stock Option (Right to Buy)	(3)	12/11/2013	Common Stock	62,273	\$ 0.04		D		
Stock Option (Right to Buy)	<u>(3)</u>	11/08/2014	Common Stock	25,947	\$ 0.04		D		
Stock Option (Right to Buy)	<u>(3)</u>	02/15/2015	Common Stock	103,788	\$ 0.04		D		
Stock Option (Right to Buy)	<u>(4)</u>	02/28/2016	Common Stock	155,682	\$ 0.05		D		
Warrant (Right to Buy)	(2)	03/27/2017	Common Stock	5,900	\$ 0.6728		I	See footnote (5)	
Warrant (Right to Buy)	<u>(2)</u>	03/27/2017	Common Stock	5,900	\$ 0.8473		I	See footnote (5)	
Warrant (Right to Buy)	<u>(2)</u>	03/27/2017	Common	5,900	\$ 1.0466		I	See footnote (5)	

Reporting Owners

	Relationships
Reporting Owner Name / Address	

	Director	10% Owner	Officer	Other
Reich Michael OPKO HEALTH, INC. 4400 BISCAYNE BOULEVARD MIAMI, FL 33137	X			

Signatures

/s/ Kate Inman, Attorney-in-Fact	01/08/2009
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The 194,604 shares of Common Stock are held by Edonjes LLC, of which Mr. Reich's children are the beneficial owners. Mr. Reich disclaims beneficial interest of the shares of Common Stock held by Edonjes LLC, except to the extent of any pecuniary interest therein.
- (2) These warrants are currently exercisable.
- (3) These options are fully vested.
- (4) 56,219 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.
- (5) These warrants of Common Stock are held by Edonjes LLC, of which Mr. Reich's children are the beneficial owners. Mr. Reich disclaims beneficial interest of the warrants to purchase shares of Common Stock held by Edonjes LLC, except to the extent of any pecuniary interest therein.

Remarks:

All securities described were acquired in a merger transaction between Acuity Pharmaceuticals, Inc. and eXegenics, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.